66 related articles for article (PubMed ID: 38475660)
1. Spatially informed gene signatures for response to immunotherapy in melanoma.
Aung TN; Warrell J; Martinez-Morilla S; Gavrielatou N; Vathiotis I; Yaghoobi V; Kluger HM; Gerstein M; Rimm DL
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38837895
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma.
Chi H; Peng G; Yang J; Zhang J; Song G; Xie X; Strohmer DF; Lai G; Zhao S; Wang R; Yang F; Tian G
Front Endocrinol (Lausanne); 2024; 15():1421538. PubMed ID: 38784067
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract][Full Text] [Related]
4. Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma.
Lin K; Zhou Y; Lin Y; Feng Y; Chen Y; Cai L
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189408
[TBL] [Abstract][Full Text] [Related]
5. Identification of a pyroptosis-associated long non-coding RNA signature for predicting the immune status and prognosis in skin cutaneous melanoma.
Wu L; Liu G; He YW; Chen R; Wu ZY
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5597-5609. PubMed ID: 34604952
[TBL] [Abstract][Full Text] [Related]
6. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer.
Zhou M; Zhang Z; Bao S; Hou P; Yan C; Su J; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32382761
[TBL] [Abstract][Full Text] [Related]
7. Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization.
Cui Z; Liang Z; Song B; Zhu Y; Chen G; Gu Y; Liang B; Ma J; Song B
Front Endocrinol (Lausanne); 2023; 14():1180732. PubMed ID: 37229449
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of ferroptosis-related lncRNA signature and immune-related gene signature for predicting the prognosis of cutaneous melanoma patients.
Xiong K; Wang Z; Hounye AH; Peng L; Zhang J; Qi M
Apoptosis; 2023 Jun; 28(5-6):840-859. PubMed ID: 36964478
[TBL] [Abstract][Full Text] [Related]
9. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
Kim SW; Kim YI; Mustafa B; Kim MJ; Jeong G; Ahn SM; Lim SB; Yu CS; Kim JC; Hong SM; Park IJ
Mod Pathol; 2021 Jan; 34(1):141-160. PubMed ID: 32709987
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous melanoma and the immunotherapy revolution (Review).
Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M
Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963
[TBL] [Abstract][Full Text] [Related]
11. Advanced malignant melanoma successfully treated with dacarbazine following anti-PD-1/CTLA-4 treatment.
Narahira A; Yanagi T; Kitamura S; Maeda T; Hata H; Asano T; Nozaki A; Kato T; Watari H; Shimizu H
Int J Dermatol; 2020 Nov; 59(11):e414-e416. PubMed ID: 32496569
[No Abstract] [Full Text] [Related]
12. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma.
Mao S; Li Y; Lu Z; Che Y; Huang J; Lei Y; Wang Y; Wang X; Liu C; Zheng S; Li N; Li J; Sun N; He J
Cell Oncol (Dordr); 2020 Aug; 43(4):681-694. PubMed ID: 32462608
[TBL] [Abstract][Full Text] [Related]
13. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
